trending Market Intelligence /marketintelligence/en/news-insights/trending/0xznp8891n8f1uhogcagwq2 content esgSubNav
In This List

Tenax Therapeutics regains Nasdaq compliance

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Tenax Therapeutics regains Nasdaq compliance

Tenax Therapeutics Inc. said it regained compliance with the Nasdaq Capital Market's minimum bid price requirement of $1 per share.

The Morrisville, N.C.-based specialty pharmaceutical company implemented a 1-for-20 reverse stock split of its common shares to regain compliance with Nasdaq's listing rule.